MetaCap

Obsidian Therapeutics (OBX) vs Rigel Pharmaceuticals (RIGL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Rigel Pharmaceuticals is the larger company by market cap ($754.9 million vs $741.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

OBX-31.43%RIGL+7.22%
+107%+27%-52%
Jul 27, 20261 yearNov 20, 2026
OBX-23.18%RIGL+8.91%
+81%+26%-30%
Jul 27, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

OBX versus RIGL key metrics
MetricOBXRIGL
Share price$12.00$40.09
Market cap$741.29M$754.89M
1-day change-1.23%-2.67%
YTD return—-6.40%
1-year return—-13.26%
5-year return—+44.73%
P/E ratio (TTM)—2.49
Forward P/E—8.39
EPS (TTM)$-6.52$16.07
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$294.28M
Revenue growth (YoY)—+64.15%
Net income (latest FY)—$367.02M
Gross margin—93.33%
Operating margin—42.63%
Net margin—124.72%
52-week high$49.97$52.61
52-week low$9.60$24.95
Distance from 52-week high-75.99%-23.80%
Analyst consensusstrong_buybuy
Avg. price target upside+222.25%+60.64%
Average volume511.50K248.06K
Shares outstanding61.77M18.83M
Employees87172
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Obsidian Therapeutics

OBX stock →

Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies.

Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees

About Rigel Pharmaceuticals

RIGL stock →

Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 172 employees

OBX vs RIGL FAQ

Which is bigger, Obsidian Therapeutics or Rigel Pharmaceuticals?

Rigel Pharmaceuticals (RIGL) is larger, with a market capitalization of $754.89M compared with $741.29M for Obsidian Therapeutics (OBX).

Are Obsidian Therapeutics and Rigel Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons